Egea Carlos J, Aizpuru Felipe, Pinto Jose A, Ayuela Jose M, Ballester Eugeni, Zamarrón Carlos, Sojo Agustín, Montserrat Josep M, Barbe Ferran, Alonso-Gomez Angel Ma, Rubio Ramon, Lobo Jose L, Duran-Cantolla Joaquin, Zorrilla Vanessa, Nuñez Renny, Cortés Julia, Jiménez Antonio, Cifrián Jose, Ortega Mónica, Carpizo Rosario, Sánchez Antonio, Terán Joaquin, Iglesias Luis, Fernández Carmen, Alonso Mari Luz, Cordero Jose, Roig Eulalia, Pérez Felix, Muxi Africa, Gude Francisco, Amaro Antonio, Calvo Uxio, Masa Juan F, Utrabo Isabel, Porras Yolanda, Lanchas Isabel, Sánchez Esther
Hospital Txagorritxu, Vitoria, Spain.
Sleep Med. 2008 Aug;9(6):660-6. doi: 10.1016/j.sleep.2007.06.018. Epub 2007 Sep 27.
Continuous positive airway pressure (CPAP) is an effective treatment for sleep apnea (SA), although the evidence for improving chronic heart failure (CHF) is inconclusive. Our aim was to evaluate the effect of CPAP treatment on the left ventricle ejection fraction (LVEF) among other cardiological variables in a randomized, multicenter, placebo (sham-CPAP)-controlled study.
After the selection procedure, 60 patients with CHF with LVEF<45% and SA with an apnea-hypopnea index (AHI)>10/h were evaluated at baseline, and after 3 months of treatment with optimal CPAP or sham-CPAP. The assessment was based on the LVEF, hypertension, daytime sleepiness (Epworth sleepiness scale [ESS]), quality of life (SF-36), New York Heart Scale (NYHA score), dyspnea (by using the Borg scale) and exercise tolerance (6-min walk test).
The mean AHI was normalized in the optimal CPAP group but not in the sham-CPAP group. The LVEF showed a significant improvement in the group of patients treated with CPAP (2.5; 95% CI: 0.6 to 4.3), which was not observed in the sham-CPAP group (0.0; 95% CI: -2.1 to 2.1). However, the change in the LVEF from baseline to 3 months was not significantly greater in the whole group (obstructive and Cheyne-Stokes events) treated with CPAP than in the control group (p: 0.07). In patients with only obstructive sleep apnea (OSA), who account for 83% of the total population, there was a significant improvement in the LVEF in the group of patients treated with CPAP but no such improvement in the sham-CPAP group. In this OSA group, the change in the LVEF from baseline to 3 months was significantly greater in the group treated with CPAP than in the sham-CPAP group (p: 0.03). The other variables studied were not modified. When the patients were divided according to the severity of the LVEF (a LVEF cut-off of 30%), improvement was observed in those with a LVEF>30. No changes were found in the other cardiological variables.
CPAP therapy proved to be useful in patients with associated sleep-disordered breathing and CHF. The improvement was more marked in patients with a LVEF>30%. However, the increased LVEF in the CPAP group was not accompanied by changes in the other cardiological variables.
持续气道正压通气(CPAP)是治疗睡眠呼吸暂停(SA)的有效方法,尽管其改善慢性心力衰竭(CHF)的证据尚无定论。我们的目的是在一项随机、多中心、安慰剂(假CPAP)对照研究中,评估CPAP治疗对左心室射血分数(LVEF)及其他心脏变量的影响。
经过筛选程序,60例LVEF<45%且呼吸暂停低通气指数(AHI)>10次/小时的CHF合并SA患者在基线时进行评估,并在接受最佳CPAP或假CPAP治疗3个月后再次评估。评估基于LVEF、高血压、日间嗜睡(爱泼沃斯嗜睡量表[ESS])、生活质量(SF-36)、纽约心脏功能分级(NYHA评分)、呼吸困难(采用Borg量表)和运动耐力(6分钟步行试验)。
最佳CPAP组的平均AHI恢复正常,而假CPAP组未恢复正常。CPAP治疗组患者的LVEF有显著改善(2.5;95%CI:0.6至4.3),假CPAP组未观察到这种改善(0.0;95%CI:-2.1至2.1)。然而,CPAP治疗的整个组(阻塞性和陈-施呼吸事件)从基线到3个月LVEF的变化并不比对照组显著更大(p:0.07)。在仅患有阻塞性睡眠呼吸暂停(OSA)的患者中,OSA患者占总人群的83%,CPAP治疗组患者的LVEF有显著改善,而假CPAP组没有这种改善。在这个OSA组中,从基线到3个月CPAP治疗组的LVEF变化比假CPAP组显著更大(p:0.03)。研究的其他变量没有改变。当根据LVEF的严重程度(LVEF临界值为30%)对患者进行分组时,LVEF>30%的患者有改善。其他心脏变量未发现变化。
CPAP治疗被证明对合并睡眠呼吸障碍和CHF的患者有用。LVEF>30%的患者改善更明显。然而,CPAP组LVEF的增加并未伴随其他心脏变量的变化。